SUSANN O'CONNOR: Open Payments
NPI 1528009784 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$484 in 24 payments from 11 companies in 2025. Trend: 2023 $878 · 2024 $325 · 2025 $484
Food & beverage: $484
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $109 |
| Amgen Inc. | 5 | $97 |
| Novartis Pharmaceuticals Corporation | 3 | $75 |
| Lilly USA, LLC | 3 | $54 |
| Corcept Therapeutics | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
Products named: Kerendia, LEQVIO, MOUNJARO, REPATHA, TEPEZZA, Korlym, GVOKE HYPOPEN, BRIDION.
Industry payments across AL — which companies pay providers there.
